Best of NLA: Icosapent ethyl in COVID-19, dyslipidemia in pregnant women and more
The virtual National Lipid Association Scientific Session took place from Dec. 10 to 12, and Healio and Cardiology Today have compiled a list of the most-read news from the meeting.
Readers were most interested in the CV benefits of icosapent ethyl and its effects in COVID-19; statin initiation for girls of childbearing age; drug therapy options for NAFLD; and more.
Dyslipidemia in pregnancy, ethics, genetics among key NLA topics
Daniel Soffer, MD, clinical associate professor of medicine in the division of general internal medicine at the Perelman School of Medicine of the University of Pennsylvania, discussed his personal highlights from the meeting with Healio. Read more
CV benefits of icosapent ethyl may increase as daily EPA levels increase
Improvements in CV outcomes from hypertriglyceridemia treatment with icosapent ethyl, compared with placebo, increased as daily levels of eicosapentaenoic acid increased, according to an analysis of the REDUCE-IT trial. Read more
Icosapent ethyl appears to reduce inflammation, improve symptoms in COVID-19
In a first-in-human study, icosapent ethyl reduced levels of inflammatory biomarkers and improved symptoms in patients with COVID-19. Read more
Low LDL, high triglycerides may indicate mortality risk in COVID-19 hospitalization
Among patients hospitalized with COVID-19, LDL level below 50 mg/dL and triglycerides above 150 mg/dL were individually associated with increased odds for mortality, according to a presentation. Read more
Statin initiation for girls of childbearing age requires pregnancy planning discussion
Statin therapy at a young age is safe and effective in preventing future adverse CV events in patients at increased atherosclerotic risk, but girls and women may require counseling for pregnancy planning, a speaker reported. Read more
Race alone may not explain ASCVD risk in familial hypercholesterolemia
Race alone may not explain disparities in risk for atherosclerotic CVD among patients with familial hypercholesterolemia. Read more
Many drug therapy options exist for NAFLD
Lipid-lowering therapies, diabetes drugs and liver-related therapies are among the medication options for patients with nonalcoholic fatty liver disease. Read more
Managing dyslipidemia in pregnant women challenging
There are few evidence-based options for managing women with dyslipidemia who become pregnant or are thinking about it. Read more